🚀 VC round data is live in beta, check it out!
- Public Comps
- Optomed
Optomed Valuation Multiples
Discover revenue and EBITDA valuation multiples for Optomed and similar public comparables like Klea, InspireMD, BATM Advanced Communications, Baird Medical Investment and more.
Optomed Overview
About Optomed
Optomed PLC is a Finnish medical technology company and a manufacturer of handheld fundus cameras and screening software. The company provides AI-based screening solutions to support diagnostic processes and early detection. It develops retinal imaging technology that is patented, clinically validated, and has approvals in all key markets, including CE, FDA and NMPA. The company's products are sold via various sales channels in over 60 countries. It has two reportable segments: Devices and Software. The majority of revenue is derived from the Software segment, which offers products for optimal management of various screening operations as well as IT solutions and services for storing, viewing and working with medical images. Geographically, it generates maximum revenue from Finland.
Founded
2004
HQ

Employees
115
Website
Financials (LTM)
EV
$55M
Optomed Financials
Optomed reported last 12-month revenue of $21M and negative EBITDA of ($3M).
In the same LTM period, Optomed generated $13M in gross profit, ($3M) in EBITDA losses, and had net loss of ($7M).
Revenue (LTM)
Optomed P&L
In the most recent fiscal year, Optomed reported revenue of $20M and EBITDA of ($4M).
Optomed expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $21M | XXX | $20M | XXX | XXX | XXX |
| Gross Profit | $13M | XXX | $13M | XXX | XXX | XXX |
| Gross Margin | 64% | XXX | 64% | XXX | XXX | XXX |
| EBITDA | ($3M) | XXX | ($4M) | XXX | XXX | XXX |
| EBITDA Margin | (16%) | XXX | (22%) | XXX | XXX | XXX |
| EBIT Margin | (31%) | XXX | (35%) | XXX | XXX | XXX |
| Net Profit | ($7M) | XXX | ($8M) | XXX | XXX | XXX |
| Net Margin | (35%) | XXX | (39%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Optomed Stock Performance
Optomed has current market cap of $64M, and enterprise value of $55M.
Market Cap Evolution
Optomed's stock price is $2.96.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $55M | $64M | 0.0% | XXX | XXX | XXX | $-0.36 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOptomed Valuation Multiples
Optomed trades at 2.6x EV/Revenue multiple, and (16.1x) EV/EBITDA.
EV / Revenue (LTM)
Optomed Financial Valuation Multiples
As of April 19, 2026, Optomed has market cap of $64M and EV of $55M.
Equity research analysts estimate Optomed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Optomed has a P/E ratio of (8.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $64M | XXX | $64M | XXX | XXX | XXX |
| EV (current) | $55M | XXX | $55M | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | (16.1x) | XXX | (12.7x) | XXX | XXX | XXX |
| EV/EBIT | (8.6x) | XXX | (7.7x) | XXX | XXX | XXX |
| EV/Gross Profit | 4.1x | XXX | 4.3x | XXX | XXX | XXX |
| P/E | (8.8x) | XXX | (8.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (9.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Optomed Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Optomed Margins & Growth Rates
Optomed's revenue in the last 12 month grew by 15%.
Optomed's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Optomed's rule of 40 is 6% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Optomed's rule of X is 23% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Optomed Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | (16%) | XXX | (22%) | XXX | XXX | XXX |
| EBITDA Growth | (92%) | XXX | (72%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 6% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 23% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 99% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Optomed Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Optomed | XXX | XXX | XXX | XXX | XXX | XXX |
| Klea | XXX | XXX | XXX | XXX | XXX | XXX |
| InspireMD | XXX | XXX | XXX | XXX | XXX | XXX |
| BATM Advanced Communications | XXX | XXX | XXX | XXX | XXX | XXX |
| Baird Medical Investment | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Optomed M&A Activity
Optomed acquired XXX companies to date.
Last acquisition by Optomed was on XXXXXXXX, XXXXX. Optomed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Optomed
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOptomed Investment Activity
Optomed invested in XXX companies to date.
Optomed made its latest investment on XXXXXXXX, XXXXX. Optomed invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Optomed
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Optomed
| When was Optomed founded? | Optomed was founded in 2004. |
| Where is Optomed headquartered? | Optomed is headquartered in Finland. |
| How many employees does Optomed have? | As of today, Optomed has over 115 employees. |
| Is Optomed publicly listed? | Yes, Optomed is a public company listed on Nasdaq Helsinki. |
| What is the stock symbol of Optomed? | Optomed trades under OPTOMED ticker. |
| When did Optomed go public? | Optomed went public in 2019. |
| Who are competitors of Optomed? | Optomed main competitors are Klea, InspireMD, BATM Advanced Communications, Baird Medical Investment. |
| What is the current market cap of Optomed? | Optomed's current market cap is $64M. |
| What is the current revenue of Optomed? | Optomed's last 12 months revenue is $21M. |
| What is the current revenue growth of Optomed? | Optomed revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Optomed? | Current revenue multiple of Optomed is 2.6x. |
| Is Optomed profitable? | No, Optomed is not profitable. |
| What is the current EBITDA of Optomed? | Optomed has negative EBITDA and is not profitable. |
| What is Optomed's EBITDA margin? | Optomed's last 12 months EBITDA margin is (16%). |
| What is the current EV/EBITDA multiple of Optomed? | Current EBITDA multiple of Optomed is (16.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.